ACTU — Actuate Therapeutics Cashflow Statement
0.000.00%
- $174.81m
- $166.57m
Annual cashflow statement for Actuate Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Net Income/Starting Line | -20.2 | -24.7 | -27.3 |
Non-Cash Items | 0.634 | 0.547 | 4.25 |
Unusual Items | |||
Other Non-Cash Items | |||
Changes in Working Capital | 1.73 | 2.57 | 1.19 |
Change in Prepaid Expenses | |||
Change in Other Assets | |||
Change in Accounts Payable | |||
Change in Accrued Expenses | |||
Cash from Operating Activities | -17.8 | -21.6 | -21.8 |
Financing Cash Flow Items | — | — | -1.93 |
Other Financing Cash Flow | |||
Net Issuance / Retirement of Stock | |||
Net Issuance / Retirement of Debt | |||
Cash from Financing Activities | 19.3 | 4.13 | 27.5 |
Beginning Cash Balance | |||
Ending Cash Balance | |||
Net Change in Cash | 1.46 | -17.5 | 5.68 |